Russian vaccine update: Expert panel okays Dr Reddy's reworked protocol for Sputnik V phase 2, 3 trials

In the revised protocol, Dr Reddy's said the phase 2 trial of the Russian COVID-19 vaccine Sputnik V would include 100 subjects while phase 3 would involve 1,400 volunteers.

Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5648 in its research report dated October 05, 2020.

Russian COVID-19 vaccine update: Dr Reddy's told to submit revised application for phase 2, 3 clinical trials of Sputnik V

Dr Reddy's Laboratories has collaborated with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V COVID-19 vaccine.

Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5648 in its research report dated September 24, 2020.

Buy Dr Reddy’s Laboratories; target of Rs 5710: ICICI Direct

ICICI Direct is bullish on Dr Reddy’s Laboratories recommended buy rating on the stock with a target price of Rs 5710 in its research report dated September 18, 2020.

Brokerages see a further upside in this stock after an 85% jump year-to-date

Some brokerages say the stock could rise further in days to come owing to the company's strong FCF generation and healthy balance sheet.

Accumulate Dr. Reddy's Laboratories; target of Rs 4834: Dolat Capital

Dolat Capital recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 4834 in its research report dated September 17, 2020.

Dr Reddy's Labs shares surge 10% to hit record high

Global brokerage firm Credit Suisse is of the view that Revlimid generic cashflows should be significant (over $700 million).

Dr Reddy's launches generic ADD drug in US market

The company’s product is generic version of Janssen Pharmaceuticals’ Concerta tablets, Dr Reddy’s Laboratories said in a statement. The company’s product is generic version of Janssen Pharmaceuticals’ Concerta tablets, Dr Reddy’s Laboratories said in a statement.

USFDA ‘closes' warning letter for three sites of Dr Reddy's Laboratories

In November 2015, the company said it had received a warning letter from the US Food and Drug Administration (USFDA) for three of its sites -- active pharmaceutical ingredient (API) manufacturing facilities at Srikakulum, Andhra Pradesh, and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh.

Dr Reddy's Laboratories forays into hospital nutrition segment with Celevida Maxx in India

It is a unique addition to Dr Reddy's nutrition portfolio and is designed to help manage the nutritional needs of Cancer, Critical Care and Chronic Obstructive Pulmonary Disease (COPD) patients in India, a press release from the company said.

Coronavirus treatment | Dr Reddy's launches Avigan (Favipiravir) tablets in India

Dr Reddy's said Avigan has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19.

Hold Dr. Reddy's Laboratories; target of Rs 4326: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Dr. Reddy's Laboratories with a target price of Rs 4326 in its research report dated July 29, 2020.

Accumulat Dr Reddy's Laboratories; target of Rs 4721: Dolat Capital

Dolat Capital recommended accumulat rating on Dr Reddy's Laboratories with a target price of Rs 4721 in its research report dated July 29, 2020.

Buy Dr Reddy's Laboratories; target of Rs 5000: ICICI Direct

ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 30, 2020.

Ideas For Profit | Why investors with high risk appetite can accumulate Dr Reddy's Laboratories

Watch the video to know if Dr Reddy's meets all the criteria to garner investor interest

Dr Reddy's share price hits 52-week high post Q1 earnings

Prabhudas Lilladher downgrades, while Motilal Oswal keeps the rating 'neutral', with a target price of Rs 4,600 per share.

Dr Reddys Labs Standalone June 2020 Net Sales at Rs 3,244.40 crore, up 29.33% Y-o-Y

Dr Reddys Labs Consolidated June 2020 Net Sales at Rs 4,426.50 crore, up 14.73% Y-o-Y

Dr Reddy's share price hits 52-week high on Q1 numbers

Revenue from operations during the June quarter stood at Rs 4,418 crore, up 15 percent YoY.

Dr Reddy's Labs Q1 profit falls 13%; gross margin improves 430 bps YoY

The stock rallied 26 percent during June quarter and gained 41 percent year-to-date, largely due to demand for healthcare and pharmaceutical segments amid COVID-19 crisis.

Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%

Sharekhan sees 167 bps increase in EBITDA margin due to cost savings and better revenue performance.

Dr Reddy's Laboratories launches OTC Nicotine Polacrilex lozenges in the US

The product is a store brand version of GlaxoSmithKline Consumer Healthcare LP's Nicorette lozenges, it added.

Overall performance may be quite volatile in FY21 due to coronavirus: Dr Reddy's Laboratories

The company however remains cautiously optimistic of re-calibrating its levers to suit the new business environment, it noted.

Fujifilm to partner with Dr Reddy's to sell Avigan overseas as COVID-19 treatment

The agreement provides for Fujifilm Toyama Chemical, a unit of the Japanese company to grant Dr. Reddy's and Dubai-based Global Response Aid the right to develop, make and sell Avigan overseas and get a lump-sum license fee and royalties on sales.